Triple-Negative Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results demonstrate a significant impact of ERβ in TNBC genome activity mediated by its cooperation with regulatory multiprotein chromatin remodelling complexes, providing novel ground to devise new strategies for the treatment of these diseases based on ligands affecting the activity of this nuclear receptor or some of its protein partners.
|
31792072 |
2020 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we evaluated the characteristics, clinical behaviour and role of biomarkers (androgen receptor (AR), oestrogen receptor beta (ERβ) and p53) in metastatic TNBC.
|
31563883 |
2020 |
Triple-Negative Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patient survival according to ESR2 expression levels and TP53 mutation status was analyzed in the basal-like TNBC subgroup in the Molecular Taxonomy of Breast Cancer International Consortium (n = 308) and Roswell Park Comprehensive Cancer Center (n = 46) patient cohorts by univariate Cox regression and log-rank test.All statistical tests are two-sided.
|
30990221 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
|
30805773 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study aimed to the identification of estrogen receptor (ER)β as a novel mitochondrial target in TNBC cells, together with underlying mechanisms.
|
30873822 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Raloxifene nano-micelles effect on triple-negative breast cancer is mediated through estrogen receptor-β and epidermal growth factor receptor.
|
30615483 |
2019 |
Triple-Negative Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We show that two of the variants of ERβ, namely ERβ2 and ERβ5, control aggressiveness of TNBC by regulating hypoxic signaling through stabilization of HIF-1α.
|
29552303 |
2018 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate whether modulation of ERβ could serve as a therapeutic strategy for cancer metastasis, we examined whether the selective ERβ agonist LY500307 could suppress lung metastasis of triple-negative breast cancer (TNBC) and melanoma.
|
29592953 |
2018 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data reveal the involvement of cystatins in suppressing breast cancer progression and highlight the value of ERβ-targeted therapies for the treatment of TNBC patients.
|
30257941 |
2018 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, distinct ERβ dynamics in various cellular bio-settings such as prostate cancer (DU-145) or triple-negative breast cancer (MDA-MB-231) cells were directly observed for the first time viaFPNM staining.
|
29610818 |
2018 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, our studies for the first time revealed that TRPV2 might be a good prognostic marker for TNBC and ERβ- breast cancer patient especially for those who are treated with chemotherapy.
|
30323891 |
2018 |
Triple-Negative Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ERβ and IGF2 were found to be upregulated in our TNBC cell lines when compared to other cell types.
|
30338035 |
2018 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, we demonstrate that ERβ2 has an important role in enhancing cell proliferation and invasion, beyond modulation of ERβ and ERβ1 signalling which might contribute to the invasive characteristics of TNBC.
|
29100336 |
2017 |
Triple-Negative Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We observed androgen-dependent upregulation of aromatase and ERβ in a subset of AR expressing TNBC cell lines (MDA-MB-453, SUM-185-PE and MFM-223).
|
27848152 |
2017 |
Triple-Negative Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Lastly, immunohistochemical expression of ERβ1 in TNBC tissues was analyzed and correlated with clinicopathological features.
|
28583190 |
2017 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that the tumor suppressive effects of ERβ in TNBC result from inhibition of cell cycle progression, effects that are in part mediated by suppression of CDK1/7.
|
29228549 |
2017 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this in vitro study, we examined the role of ERβ in invasion of two triple-negative breast cancer cell lines.
|
28003019 |
2016 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function.
|
26871946 |
2016 |
Triple-Negative Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To assess ERβ effects on proliferation, ERβ expression in TNBC cells was silenced using shRNA, resulting in a significant reduction in TNBC proliferation.
|
25874233 |
2015 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells.
|
25420519 |
2015 |
Triple-Negative Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Regulation of IMP3 by EGFR signaling and repression by ERβ: implications for triple-negative breast cancer.
|
22266872 |
2012 |